Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 01 July 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

MicroRNA biomarkers in whole blood for detection of pancreatic cancer

This week's issue of the Journal of the American Medical Association identified panels of microRNAs for use in diagnosis of pancreatic cancer compared with the cancer antigen 19-9.

News image

Biomarkers for the early diagnosis of patients with pancreatic cancer are needed to improve prognosis.

Dr Nicolai Schultz and colleagues from Denmark and colleagues described differences in microRNA expression in whole blood between patients with pancreatic cancer, chronic pancreatitis, and healthy participants.

The research team identified panels of microRNAs for use in diagnosis of pancreatic cancer compared with the cancer antigen 19-9 (CA19-9).

The team performed a case-control study that included 409 patients with pancreatic cancer, and 25 with chronic pancreatitis who had been included prospectively in the Danish BIOPAC (Biomarkers in Patients with Pancreatic Cancer) study (July 2008-October 2012) plus 312 blood donors as healthy participants.

The microRNA expressions in pretreatment whole blood RNA samples were collected and analyzed in 3 randomly determined subcohorts.

38 microRNAs in whole blood were significantly dysregulated in patients
Journal of the American Medical Association

The discovery cohort included 143 patients with pancreatic cancer, 18 patients with chronic pancreatitis, and 69 healthy participants.

The training cohort included 180 patients with pancreatic cancer, 1 patient with chronic pancreatitis, and 199 healthy participants.

The validation cohort involved 86 patients with pancreatic cancer, 7 patients with chronic pancreatitis, and 44 healthy participants.

The team screended 754 microRNAs in the discovery cohort, and 38 microRNAs in the training cohort, and 13 microRNAs in the validation cohort.

The research team's main outcomes included identification of microRNA panels (classifiers) for diagnosing pancreatic cancer.

The discovery cohort demonstrated that 38 microRNAs in whole blood were significantly dysregulated in patients with pancreatic cancer compared with controls.

The team tested these microRNAs in the training cohort, and 2 diagnostic panels were constructed comprising 4 microRNAs in index I, and 10 in index II.

The test characteristics for the training cohort were index I area under the curve (AUC) of 0.86, sensitivity of 0.85, and specificity of 0.64.

The values for index II were an AUC of 0.93, sensitivity of 0.85, and specificity of 0.85.

The team found that for CA19-9, the AUC was 0.90, with a sensitivity of 0.86, and specificity of 0.99.

Performances were strengthened in the validation cohort by combining panels and CA19-9.

Compared with CA19-9 alone, the AUC for the combination of index I and CA19-9 was significantly higher.

The researchers found that the performance of the panels in patients with stage IA-IIB pancreatic cancer was index I AUC of 0.80.

Index I with CA19-9 had an AUC of 0.83; index II had an AUC of 0.91, and index II with CA19-9 had an AUC of 0.91.

Dr Schultz's team commented, "This study identified 2 diagnostic panels based on microRNA expression in whole blood with the potential to distinguish patients with pancreatic cancer from healthy controls."

"Further research is necessary to understand whether these have clinical implications for early detection of pancreatic cancer and how much this information adds to serum CA19-9."

JAMA 2014: 311(4)
23 January 2014

Go to top of page Email this page Email this page to a colleague

 01 July 2016 
Aspirin and colorectal cancer
 01 July 2016 
Outcome measures in celiac disease
 01 July 2016 
Growth factor activity and IBD
 30 June 2016 
Staging system for familial adenomatous polyposis
 30 June 2016 
Antibiotics in children and obesity
 30 June 2016 
IBS-type symptoms in pediatric IBD
 29 June 2016 
Hep C eradication in people who inject drugs
 29 June 2016 
Anti-tumor necrosis factor in mothers and newborns
 29 June 2016 
Progression to esophageal carcinoma in Barrett's
 28 June 2016 
Gastric cancer screening in the USA
 28 June 2016 
Acute severe ulcerative colitis
 28 June 2016 
Cancer recurrence after immune-suppressive therapies
 27 June 2016 
Epidemiology of NAFLD
 27 June 2016 
Tobacco smoking and ulcerative colitis
 27 June 2016 
The Toronto Consensus for H. pylori treatment
 24 June 2016 
Statins and colorectal cancer in IBD
 24 June 2016 
Dietary trends in the USA
 24 June 2016 
Fibre for chronic idiopathic constipation
 23 June 2016 
Biomarker for eosinophilic esophagitis diagnosis
 23 June 2016 
Touch screens in the IBD outpatient clinic
 23 June 2016 
Adverse events after colonoscopy bowel preparations
 22 June 2016 
Benefits and harms of colorectal cancer screening
 22 June 2016 
IBS symptoms in IBD
 22 June 2016 
Outcomes among US veterans with Hep B
 21 June 2016 
Screening for colorectal cancer
 21 June 2016 
Tenofovir and Hep B transmission in mothers
 21 June 2016 
Access to liver subspecialty care and survival
 20 June 2016 
Genes for colorectal cancer risk
 20 June 2016 
Patients and gastroenterologists’ perceptions on IBD
 20 June 2016 
Hep C treatment in people who inject drugs
 17 June 2016 
Noninvasive markers of liver fibrosis
 17 June 2016 
Predictors of starting with long-term PPIs
 17 June 2016 
Extrahepatic manifestations of Hep C
 16 June 2016 
Assessing progression of NAFLD
 16 June 2016 
Endotracheal intubation and endoscopy unit efficiency metrics
 16 June 2016 
Bile acid diarrhea
 15 June 2016 
Consensus for acute severe ulcerative colitis
 15 June 2016 
Dental erosions in GERD
 15 June 2016 
Pharmacological treatments for obesity with weight loss
 14 June 2016 
Antibiotics and gut inflammation
 14 June 2016 
Liver-related mortality in the developed world
 14 June 2016 
Hep C patient outcomes treated with different anti-viral regimens
 13 June 2016 
Obesity in the USA
 13 June 2016 
Celiac disease drug development
 13 June 2016 
Pneumonia risk in celiac disease
 10 June 2016 

Celiac disease drug development

 10 June 2016 
Rectal cancer surgery checklist
 10 June 2016 
Breath as a marker for IBS
 09 June 2016 
Psychological morbidity in young people with IBD
 09 June 2016 
Predicting hepatic encephalopathy in cirrhosis
 09 June 2016 
Evaluation of endoscopic findings from patients with Crohn's
 08 June 2016 
Adult obesity trends in the USA
 08 June 2016 
Pediatric IBD unclassified vs other IBD
 08 June 2016 
Dark chocolate and NASH oxidation
 07 June 2016 
Flexible endoscopy for Zenker's diverticulum
 07 June 2016 
Predicting risk of hepatic encephalopathy in cirrhosis
 07 June 2016 
Electronic learning system for colon capsule endoscopy
 06 June 2016 
Disturbed sleep and symptoms in IBS
 06 June 2016 
Oral contraceptives and Crohn’s complications
 06 June 2016 
Eosinophilic esophagitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us